Anuradha Krishnamurthy

MBBS
Hematologic Oncology

Cancers Treated:

Colon Colorectal Esophageal Gallbladder & Bile Duct Liver Neuroendocrine Tumors Pancreatic Stomach

Specializing In:

Treatment Refractory Metastatic Colorectal Cancer Hepatic Artery Infusion Pump for liver metastases Cellular Therapies for Solid Tumors Phase I clinical Trials

Research Interests:

Treatment Refractory Metastatic Colorectal Cancer Cellular Therapies for Solid Tumors Phase I clinical Trials

About Anuradha Krishnamurthy

Biography:

As a medical oncologist at Roswell Park Comprehensive Cancer Center, my primary interests are patient care and clinical research. We work as a team to meet patient needs and provide holistic care. My patients are my motivation for research. There is a large unmet need for new therapies in cancer. Novel drug development through early phase clinical trials is an integral part of cancer care. T cell-based therapies are new avenues of treatment that have shown great promise in hematologic malignancies and now in certain solid tumors. Roswell Park is on the forefront of this research and I am very excited to be a part of the team. I am also involved in establishing a hepatic artery infusion pump program at Roswell Park for metastatic colorectal cancer and intrahepatic cholangiocarcinoma patients. This option allows us to target the liver better than systemic therapy alone.

I have authored/co-authored several peer reviewed publications. Through my work here at Roswell, I hope to continue providing excellent patient care and be involved in the development of novel, personalized therapies for cancer.

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Medicine
  • Associate Director of Early Phase Clinical Trials for Solid Tumor Cell Therapies

Background

Education and Training:

  • 2010 - MD - University of Sydney, Sydney, Australia
  • 2005 - BS - Physiology and Anthropology, University of Toronto, Toronto, Canada

Residency:

  • 2011-2014 - Internal Medicine, University of Ottawa, Ottawa, Ontario

Fellowship:

  • 2014-2016 - Medical Oncology, Queen's University, Kingston, Ontario
  • 2016-2018 – Developmental Therapeutics, University of Colorado, Denver, CO

Board Certification:

  • American Board of Internal Medicine - Internal Medicine and Medical Oncology
  • Fellow of the Royal College of Physicians of Canada - Internal Medicine and Medical Oncology

Professional Memberships:

  • American Society of Clinical Oncology
  • Society for Immunotherapy of Cancer

Professional Experience:

  • 2018-2022 - Assistant Professor of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

Honors & Awards:

  • 2017 - ASCO/AACR Methods in Clinical Cancer Research Workshop
  • 2017 - GI ASCO Merit Award
  • 2016 - AAADV Regional Scholars Workshop, Awarded Registration Scholarship
  • 2010 - Graduated with Honors, Sydney Medical School, University of Sydney
  • 2005 - Dean's List, "Aiming for the Top" Scholarship, University of Toronto

Clinical Trials

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Learn More

Publications

Kuang C, Park Y, Augustin RC, Lin Y, Hartman DJ, Seigh L, Pai RK, Sun W, Bahary N, Ohr J, Rhee JC, Marks SM, Beasley HS, Shuai Y, Herman JG, Zarour HM, Chu E, Lee JJ, Krishnamurthy A. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. Clin Epigenetics. 2022 Jan 6;14(1):3. doi: 10.1186/s13148-021-01226-y. PMID: 34991708; PMCID: PMC8740438.

Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res. 2018 Sep 15;78(18):5398-407. PubMed PMID: 30042150; PMCID: PMC6139073.

Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. 2018 May; 185:122-34. PubMed PMID: 29269044.

Krishnamurthy A, Jimeno A. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today (Barc). 2017 Apr;53(4):217-37. PubMed PMID: 28492290.

Gorgulho CM, Krishnamurthy A, Lanzi A, Galon J, Housseau F, Kaneno R, Lotze MT. Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. J Immunother. 2021 Feb-Mar 01;44(2):49-62. PubMed PMID: 33416261; PMCID: PMC8092416.